Patients diagnosed with alpha-1 antitrypsin deficiency must exercise caution and generally avoid specific medications that can exacerbate liver inflammation or compromise respiratory function. Hepatotoxic drugs, certain non-steroidal anti-inflammatory agents, and specific metabolic byproducts that stress hepatic pathways should be minimized because the liver is already burdened by accumulating mutant alpha-1 protein polymers. Additionally, respiratory depressants and sedatives must be managed carefully by attending physicians to prevent exacerbating chronic obstructive pulmonary disease symptoms or respiratory depression in susceptible individuals.